Trials / Conditions / HER-2 Protein Overexpression

HER-2 Protein Overexpression

20 registered clinical trials studyying HER-2 Protein Overexpression — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors NCT06695845	Jazz Pharmaceuticals	Phase 2
Recruiting	Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer NCT06187506	Fudan University	Phase 2
Unknown	DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC NCT06055153	Changhai Hospital	Phase 1 / Phase 2
Active Not Recruiting	Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Tr NCT05480384	Brown University	Phase 2
Completed	Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations NCT05904730	Lynkcell Europe	Phase 1
Recruiting	PRE-I-SPY Phase I/Ib Oncology Platform Program NCT05868226	QuantumLeap Healthcare Collaborative	Phase 1
Terminated	Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors NCT05511844	Orum Therapeutics USA, Inc.	Phase 1
Unknown	Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Eso NCT05170256	Morten Mau-Sørensen	Phase 2
Recruiting	HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced NCT04995003	Baylor College of Medicine	Phase 1
Withdrawn	ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With NCT04602117	QuantumLeap Healthcare Collaborative	Phase 1
Withdrawn	Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advance NCT04464967	NKGen Biotech, Inc.	Phase 1 / Phase 2
Active Not Recruiting	CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors NCT04660929	Carisma Therapeutics Inc	Phase 1
Suspended	Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive So NCT04650451	Bellicum Pharmaceuticals	Phase 1
Active Not Recruiting	Testing a New Imaging Agent to Identify Cancer NCT04692831	Memorial Sloan Kettering Cancer Center	Phase 1
Unknown	Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive S NCT04215159	Jin-Hee Ahn	Phase 2
Unknown	The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor NCT04179656	Tianjin Medical University Second Hospital	Phase 2
Completed	Trastuzumab in HER2-positive Biliary Tract Cancer NCT03613168	Changhoon Yoo	Phase 2
Terminated	Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tum NCT03680560	Cogent Biosciences, Inc.	Phase 1
Terminated	Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 NCT03630809	H. Lee Moffitt Cancer Center and Research Institute	Phase 2
Terminated	Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product NCT02840110	Cogent Biosciences, Inc.	—